Research graph
References from Therapie des Trockenen Auges – aktuelle Empfehlungen nach DEWS-III-Report. Local targets link to admitted publications; unresolved targets remain external evidence.
TFOS DEWS III: Management and Therapy
10.1016/j.ajo.2025.05.039 · 2025 · External reference
TFOS DEWS III: Diagnostic Methodology
10.1016/j.ajo.2025.05.033 · 2025 · External reference
TFOS DEWS III: Executive Summary
10.1016/j.ajo.2025.09.035 · 2026 · External reference
TFOS DEWS III: Digest
10.1016/j.ajo.2025.05.040 · 2025 · External reference
TFOS DEWS II Diagnostic Methodology Report
10.1016/j.jtos.2017.05.001 · 2017 · External reference
Compliance and Subjective Patient Responses to Eyelid Hygiene
10.1097/icl.0000000000000258 · 2017 · External reference
[Gas permeable scleral lenses as a conservative treatment option for extreme corneal ectasis and severe dry eye]
10.1007/s00347-004-1101-6 · 2005 · External reference
Efficacy of 0,18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease
10.1016/j.jfo.2011.07.017 · 2012 · External reference
Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease
10.4103/ijo.ijo_2666_22 · 2011 · External reference
Effect of hypotonic 0,4% hyaluronic acid drops in dry eye patients: a crossover study
10.1097/ico.0b013e318180e55c · 2008 · External reference
Hyaluronic acid in the treatment of dry eye disease
10.1111/aos.15159 · 2022 · External reference
A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome
10.3390/ijerph18052383 · 2021 · External reference
Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye
10.1089/jop.2012.0066 · 2012 · External reference
Tear film osmolarity measurements in dry eye disease using electrical impedance technology
10.1097/ico.0b013e31821de383 · 2011 · External reference
Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy
10.1097/ico.0000000000000273 · 2014 · External reference
The effect of microblepharon exfoliation on clinical correlates of contact lens discomfort
10.1097/opx.0000000000001354 · 2019 · External reference
Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction
10.1167/iovs.14-15764 · 2015 · External reference
Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction
10.2147/opth.s213664 · 2019 · External reference
Wenn Tränenersatzmittel nicht mehr ausreichen: die Bedeutung von Entzündungsprozessen beim Trockenen Auge. Praktische Aspekte einer antientzündlichen Therapie des Trockenen Auges [If Artificial Tears Aren’t Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease]
10.1055/a-1115-4756 · 2020 · External reference
Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: A 1-year, multicenter, randomized, placebo-controlled study
10.1097/ico.0000000000000803 · 2016 · External reference
Autologous serum compared to artificial tear drops for dry eye disease
10.5867/medwave.2021.05.8213 · 2021 · External reference
Diquafosol ophthalmic solution 3%: a review of its use in dry eye
10.1007/s40265-015-0409-7 · 2015 · External reference
A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease
10.1016/j.ophtha.2016.09.023 · 2017 · External reference
n-3 fatty acid supplementation for the treatment of dry eye disease
10.1056/nejmoa1709691 · 2018 · External reference
Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial
10.1001/jamaophthalmol.2013.195 · 2013 · External reference
Treatment of dry eye from laser-assisted in situ keratomileusis with recombinant human nerve growth factor (Cenegermin)
10.1097/ico.0000000000002554 · 2021 · External reference
Transient receptor potential channels: Important players in ocular pain and dry eye disease
10.3390/pharmaceutics14091859 · 2022 · External reference
